Flurithromycin ethylsuccinate

Drug Profile

Flurithromycin ethylsuccinate

Alternative Names: Flurizic; Mizar; P 0522; Ritro

Latest Information Update: 29 Apr 2003

Price : $50

At a glance

  • Originator Pfizer
  • Developer Pfizer; Pierrel
  • Class Antibacterials; Macrolides
  • Mechanism of Action Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Oral infections; Respiratory tract infections

Most Recent Events

  • 16 Apr 2003 Pharmacia Corporation has been acquired by, and merged into, Pfizer
  • 13 May 1998 Launched for Oral infections in Italy (PO)
  • 13 May 1998 Launched for Respiratory tract infections in Italy (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top